Phase I trial of pazopanib in patients with advanced cancer.
about
Pazopanib in the management of advanced soft tissue sarcomasSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesPazopanib in sarcomas: expanding the PALETTEProfile of pazopanib and its potential in the treatment of epithelial ovarian cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerActivating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Developmental therapeutics for inflammatory breast cancer: Biology and translational directionsNeoadjuvant Therapy in Differentiated Thyroid CancerPazopanib in the treatment of soft tissue sarcomaSafety and tolerability of pazopanib in the treatment of renal cell carcinomaPazopanib, a new therapy for metastatic soft tissue sarcomaThe B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor modelsA cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS.Computational repositioning and preclinical validation of pentamidine for renal cell cancer.Pazopanib: approval for soft-tissue sarcoma.Effect of pazopanib on tumor microenvironment and liposome deliveryThe PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinomaExperimental approaches for the treatment of malignant gliomas.Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumorsPazopanib for the treatment of patients with advanced renal cell carcinomaIn comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.Targeting angiogenesis in advanced cervical cancer.Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.Pazopanib for the treatment of soft-tissue sarcoma.Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic EffectsEfficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I studyCritical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinomaTyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib.Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.
P2860
Q26746205-CEE1A54B-DD79-4A25-A558-27D2393C1833Q26751274-BE660A29-20DB-4B28-843D-B97EB26185F1Q26825050-2C45225B-E6EC-43F9-954C-0FF46B9BB956Q27011840-80EF726E-EE09-461F-B610-94BC6A323B77Q27024235-10415ECD-5F1B-45B7-8B06-DBE1FAD4EA0EQ27852954-45C4A62E-63BC-45A0-85D3-27F4709435DEQ28075322-12F38D7C-55B1-47E6-B6D8-78D19CF6CDC7Q28078879-ADB8D0B1-D411-4658-8F3F-B79DF14210B6Q28269229-E1E28117-9515-4D6E-BCBD-3C47877D8595Q28272429-F914630F-0BB8-42EF-B95A-41B08374A708Q28287163-F33E460A-9544-4CBD-A708-1F0AC38BBF49Q28744228-61908835-FFEF-4C95-AE62-AF00C73B26A9Q30396736-A0C2C8E0-6866-4609-B0BD-4339E12AB682Q33404877-CE6F2AC0-E224-46AF-BCFB-BB108C3B5C07Q33412909-6C8A85EA-E23E-4325-88A3-A9A7EB8122CDQ33430940-AE622409-B61F-42DB-8BDB-5F43C3004211Q33590458-1D2C4A30-0508-4DD5-BD07-B830CB29B830Q33633424-2322A83E-69BD-4B37-8975-06749392C458Q33826472-FC2C0166-671A-4B9C-A79A-B8CB65B831B2Q33875574-471127C4-BB5B-47E0-B109-654BE2E13DD4Q33885782-E210331A-C237-44B0-A32A-5DB8908804FFQ34018204-5F06BFC8-34B9-4A86-BE5B-8E9EF24A9C22Q34052424-2E60CC8F-042F-4184-9922-C1145B8D5F3EQ34064359-767148EC-1D28-4BCC-B42C-8DC72B03E939Q34127138-529FCA58-D17B-46FE-8DDF-B2E67E78D610Q34129269-9A7DB527-DD06-4608-8550-5A56030DC60CQ34207205-FB463231-B680-445B-9002-56A3A6F402F1Q34334533-4DD294C6-CC23-49D0-8688-E0B4A365994EQ34389368-2244D382-011A-4386-AE29-3FD655769091Q34499668-A55E5F6D-719E-4D44-B5E3-47D880C20323Q34645938-B0790376-F843-4AF6-B620-D47B20F869EEQ34659530-C0D13576-292D-4DE6-8615-4F746067777EQ34670026-1298C910-1E8A-4C49-B8EC-AFCCFB020FA8Q35023367-AABC90A7-D50C-481A-9739-7CBD538F5097Q35074974-14D06F43-6F58-431D-AE94-2ECC70314EC0Q35212949-F56E7D78-5818-4395-BF4E-224E0511A722Q35534962-CB457BEC-0E7B-4A7E-9B85-F4819DDC1D48Q35583837-CDD83D10-3778-44A3-9211-441484C4F4F1Q35584239-888E21AD-7850-436D-8D59-8484D1505E2CQ35599819-59E2308B-4034-4425-8694-DB8CA3D1407C
P2860
Phase I trial of pazopanib in patients with advanced cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Phase I trial of pazopanib in patients with advanced cancer.
@en
Phase I trial of pazopanib in patients with advanced cancer.
@nl
type
label
Phase I trial of pazopanib in patients with advanced cancer.
@en
Phase I trial of pazopanib in patients with advanced cancer.
@nl
prefLabel
Phase I trial of pazopanib in patients with advanced cancer.
@en
Phase I trial of pazopanib in patients with advanced cancer.
@nl
P2093
P1476
Phase I trial of pazopanib in patients with advanced cancer.
@en
P2093
A Benjamin Suttle
Afshin Dowlati
Diana M Gibson
Elmar M Merkle
Herbert I Hurwitz
Jeffrey P Hodge
Lini Pandite
Shawna Savage
Shermini Saini
P304
P356
10.1158/1078-0432.CCR-08-2740
P407
P577
2009-06-09T00:00:00Z